1. Home
  2. HALO vs CRDO Comparison

HALO vs CRDO Comparison

Compare HALO & CRDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Halozyme Therapeutics Inc.

HALO

Halozyme Therapeutics Inc.

N/A

Current Price

$107.93

Market Cap

12.0B

Sector

Health Care

ML Signal

N/A

Logo Credo Technology Group Holding Ltd

CRDO

Credo Technology Group Holding Ltd

N/A

Current Price

$208.62

Market Cap

50.7B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
HALO
CRDO
Founded
1998
2008
Country
United States
Cayman Islands
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Semiconductors
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
12.0B
50.7B
IPO Year
2001
2022

Fundamental Metrics

Financial Performance
Metric
HALO
CRDO
Price
$107.93
$208.62
Analyst Decision
Buy
Strong Buy
Analyst Count
9
19
Target Price
$99.56
★ $280.10
AVG Volume (30 Days)
2.0M
★ 8.3M
Earning Date
11-02-2026
09-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 765.52
EPS
★ 3.11
0.67
Revenue
$151,862,000.00
★ $1,335,116,000.00
Revenue This Year
$32.72
$87.36
Revenue Next Year
$10.61
$54.96
P/E Ratio
★ $36.16
$288.95
Revenue Growth
N/A
★ 205.68
52 Week Low
$61.23
$86.49
52 Week High
$116.85
$308.67

Technical Indicators

Market Signals
Indicator
HALO
CRDO
Relative Strength Index (RSI) 54.81 52.72
Support Level $104.49 $181.43
Resistance Level $111.15 $210.97
Average True Range (ATR) 3.04 8.98
MACD -0.71 4.72
Stochastic Oscillator 42.53 76.40

Price Performance

Historical Comparison
HALO
CRDO

About HALO Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

About CRDO Credo Technology Group Holding Ltd

Credo Technology Group Holding Ltd provides connectivity solutions for AI-driven applications, cloud computing, and hyperscale networks. Its high-speed copper and optical interconnect products support data infrastructure demands. The Company's product portfolio includes ZeroFlap (ZF) Active Electrical Cables (AECs), ZF optical transceivers, OmniConnect memory solutions, and retimers and DSPs for optical and copper Ethernet and PCIe, leveraging the PILOT diagnostic and analytics software platform. Its products are based on Serializer/Deserializer (SerDes) and Digital Signal Processor (DSP) technologies and include integrated circuits (ICs), Active Electrical Cables (AECs), SerDes Chiplets, and SerDes IP licensing solutions. The United States generates the maximum revenue.

Share on Social Networks: